Christy J. Oliger
CIK 1822092 · last filed 2026-07-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$30.2K
Companies
9
Total Filings
30
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $27.51 | — | $0 | 1 | 2026-07-29 |
| NUVL | Director | 0 | $123.96 | $0 | $0 | 3 | 2026-07-15 |
| VERA | Director | — | $32.02 | — | $0 | 3 | 2026-05-26 |
| KPTI | Director | 15,508 | $1.95 | $30.2K | $0 | 7 | 2026-05-26 |
| REPL | Director | — | $12.86 | — | $0 | 6 | 2026-04-07 |
| LAVA Therapeutics NV (LVTX) Delisted | Director | — | $1.74 | — | $0 | 2 | 2025-11-17 |
| RayzeBio, Inc. (RYZB) Delisted | Director | — | $62.49 | — | $0 | 1 | 2024-02-27 |
| REATA PHARMACEUTICALS INC (RETA) Delisted | Director | 0 | $172.36 | $0 | $0 | 5 | 2023-09-26 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | — | $54.99 | — | $0 | 2 | 2022-07-01 |
Recent Filings · Page 3 of 3
30 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-07-01 | Sierra Oncology, Inc. (SRRA) Delisted | Disp (D) | — | $0 | EDGAR |
| 2022-06-09 | REATA PHARMACEUTICALS INC (RETA) Delisted | Grant (A) | +3,883 | $135.0K | EDGAR |
| 2022-05-20 | KPTI | Grant (A) | — | $0 | EDGAR |
| 2022-04-05 | REPL | Grant (A) | — | $0 | EDGAR |
| 2021-12-03 | REPL | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | REATA PHARMACEUTICALS INC (RETA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-04 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | KPTI | Grant (A) | — | $0 | EDGAR |
| 2021-04-16 | REATA PHARMACEUTICALS INC (RETA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-31 | KPTI | Grant (A) | — | $0 | EDGAR |
Showing 21–30 of 30
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.